The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
If approved, DTX401 would be the first treatment to address the disease at its root cause
Subscribe To Our Newsletter & Stay Updated
